Abstract 2556: Phosphatase nanozyme combination with kinase inhibitor for decreasing prostate cancer cell viability

Abstract

Background: Phosphatase has been well studied in anti-cancer research. The dietary amino acid cysteine plays essential roles in protein structure by disulfide bonds, metal ion binding, detoxification, and many metabolic functions. Cysteine has been shown in inducing human bladder cancer cells apoptosis. However, the cysteine mediated nanoparticles enzyme (nanozyme) activity and their function, signaling pathways are yet unknown. We aim to test whether the cysteine mediated nanoparticles nanozyme activity of phosphatase could enhance targeting of kinases. Methods: Fresh L-cysteine were applied for synthesis of less than 200 nm sized nanozyme. The phosphatase enzyme activity was measured using NBT/BCIP substrate. Scanning electron microscopy, transmission electron microscopy were used for nanoparticle analysis. Cell viability was measured by crystal violet staining of cells. Results: L-cysteine at 0.1mg/mL combined with MET inhibitor (1µm or 5µm) showed the better effect of enhanced efficacy and decreased the viability of prostate cancer cells compared to inhibitor alone or cysteine. Combination did not affect the phosphatase activity of cysteine nanozyme. Conclusion: L-cysteine may be applied to be combined with kinase inhibitors in drug delivery for increased efficacy. Citation Format: Arailym Myrzagaliyeva, Guldan Nazarbek, Sandugash Myrzagali, Amr Amin, Yingqiu Xie. Phosphatase nanozyme combination with kinase inhibitor for decreasing prostate cancer cell viability [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2556.